| Autor: |
Roboz, Gail J., Sugita, Mayumi, Mosquera, Juan Miguel, Wilkes, David C, Nataraj, Sarah, Jimenez-Flores, Reyna A, Bareja, Rohan, Yan, LunBiao, Eng, Kenneth W, Croyle, Jaclyn A, MacDonald, Theresa Y, Noorzad, Zohal, Pancirer, Danielle, Cheng, Shuhua, Xiang, Jenny Z, Olson, Luke, Rickman, David, Tam, Wayne, Rubin, Mark A., Beltran, Himisha, Sboner, Andrea, Van Besien, Koen, Morgan, Bob, Hassane, Duane C., Elemento, Olivier, Chiosis, Gabriela, Guzman, Monica L. |
| Zdroj: |
Blood; November 2018, Vol. 132 Issue: 1, Number 1 Supplement 1 p1435-1435, 1p |
| Abstrakt: |
The epichaperome is a new cancer target defined, in part, by changes in the interaction strength between chaperone and co-chaperone proteins to form stable hyperconnected networks that support oncoprotein stability and are vital for tumor survival (Nature 2016, Nature Rev Cancer 2018 and Nature Med 2018). Cancers with this altered chaperone configuration may become susceptible to drugs that target the epichaperome, such as the inhibitor PU-H71. We have developed a novel flow cytometry-based test, the PU-FITC binding assay, to evaluate epichaperome levels at the single cell level and identify patients who are most likely to respond to PU-H71 treatment. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
